TY - JOUR
T1 - Longitudinal Study of the Ocular Complications of AIDS. 1. Ocular Diagnoses at Enrollment
AU - Jabs, Douglas A.
AU - Van Natta, Mark L.
AU - Holbrook, Janet T.
AU - Kempen, John H.
AU - Meinert, Curtis L.
AU - Davis, Matthew D.
N1 - Funding Information:
Supported by cooperative agreements from the National Eye Institute, Bethesda, Maryland, to Johns Hopkins University School of Medicine (no. U10 EY 08052), Johns Hopkins University Bloomberg School of Public Health (no. U10 EY 08057), and University of Wisconsin, Madison (no. U10 EY 08067). Additional support provided by the National Center for Research Resources, Bethesda, Maryland, through the General Clinical Research Center (grant nos. 5MO1 RR 00188 [Baylor College of Medicine], MO1 RR 00052 [Johns Hopkins University School of Medicine], 5MO1 RR 05096 [Louisiana State University, Tulane, Charity Hospital], 5MO1 RR 00865 [University of California, Los Angeles], 5MO1 RR 05280 [University of Miami], 5M01 RR00046 [University of North Carolina], 5MO1 RR 00043 [University of Southern California], 5MO1 RR 00047 [Weill Medical College of Cornell University]). Support also provided through cooperative agreements U01 AI 27674 (Louisiana State University), U01 AI 27660 (University of California, Los Angeles), U01 AI 276670 (University of California, San Diego), U01 AI 27663 (University of California, San Francisco), U01 AI 25858 (University of North Carolina), U01 AI 25903 (Washington University at St. Louis), and U01 AI 32783 (University of Pennsylvania).
PY - 2007/4
Y1 - 2007/4
N2 - Objective: To report the prevalence of ocular complications of AIDS in the era of highly active antiretroviral therapy (HAART). Design: Cohort study. Participants: Patients with AIDS, 13 years or older. Methods: History, eye examination, and laboratory testing at enrollment. Main Outcome Measure: Frequency of ocular complications at enrollment. Results: As of March 31, 2003, 1632 participants with AIDS were enrolled. The cohort had a history of severe immune deficiency, as evidenced by a median nadir CD4+ T-cell count of 30 cells per microliter. At enrollment, the median CD4+ T-cell count was 164 cells per microliter. CD4+ T-cell counts were <50 in 24.1% but ≥100 in 63.6% and ≥200 in 43.0%. Cytomegalovirus (CMV) retinitis was present in 22.1%, whereas other ocular opportunistic infections each were present in ≤0.6%. The incidence of CMV retinitis estimated from retrospective data was 5.60/100 person-years. Of the 360 patients with CMV retinitis, 22.5% were newly diagnosed at enrollment, and the remainder had more long-standing CMV retinitis (median, 2.8 years). Conclusions: Although there is the possibility of oversampling patients with AIDS and ocular complications (as compared with a random sample), which would lead to increased estimates of prevalent and incident ocular morbidities, these data still suggest a substantial decline in the incidence of CMV retinitis from the pre-HAART era. Nevertheless, new cases of CMV retinitis continue to occur, and there is a population of patients with long-standing retinitis who will require management.
AB - Objective: To report the prevalence of ocular complications of AIDS in the era of highly active antiretroviral therapy (HAART). Design: Cohort study. Participants: Patients with AIDS, 13 years or older. Methods: History, eye examination, and laboratory testing at enrollment. Main Outcome Measure: Frequency of ocular complications at enrollment. Results: As of March 31, 2003, 1632 participants with AIDS were enrolled. The cohort had a history of severe immune deficiency, as evidenced by a median nadir CD4+ T-cell count of 30 cells per microliter. At enrollment, the median CD4+ T-cell count was 164 cells per microliter. CD4+ T-cell counts were <50 in 24.1% but ≥100 in 63.6% and ≥200 in 43.0%. Cytomegalovirus (CMV) retinitis was present in 22.1%, whereas other ocular opportunistic infections each were present in ≤0.6%. The incidence of CMV retinitis estimated from retrospective data was 5.60/100 person-years. Of the 360 patients with CMV retinitis, 22.5% were newly diagnosed at enrollment, and the remainder had more long-standing CMV retinitis (median, 2.8 years). Conclusions: Although there is the possibility of oversampling patients with AIDS and ocular complications (as compared with a random sample), which would lead to increased estimates of prevalent and incident ocular morbidities, these data still suggest a substantial decline in the incidence of CMV retinitis from the pre-HAART era. Nevertheless, new cases of CMV retinitis continue to occur, and there is a population of patients with long-standing retinitis who will require management.
UR - http://www.scopus.com/inward/record.url?scp=33947605551&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2006.11.008
DO - 10.1016/j.ophtha.2006.11.008
M3 - Article
C2 - 17258320
AN - SCOPUS:33947605551
SN - 0161-6420
VL - 114
SP - 780-786.e3
JO - Ophthalmology
JF - Ophthalmology
IS - 4
ER -